This core, coordinated by Dr. Ambinder, will characterize diagnostic biopsy specimens and evaluate serology. Hodgkin's specimens from patients identified prospectively in Boston or Connecticut or retrospectively through the or through the military bank will be evaluated. Each will be reviewed by Drs. Risa Mann and Michael Borowitz, both nationally recognized hematopathologists. Tissues will be evaluated by conventional light microscopy with hematoxylin and eosin and by immunoperoxidase with a standard panel of antigens including CD15 (LeuM1) and CD3O (Ki1). Biopsies will be classified as Hodgkin's disease or other, and cases of Hodgkin's disease will be subcategorized as lymphocyte predominant, nodular sclerosis, mixed cellularity, lymphocyte depleted, lymphocyte-rich classical Hodgkin's or unclassifiable Hodgkin's. Specimens will be studied by in situ hybridization (for EBER1) and antigen detection by immunohistochemistry (LMP1 and EBNA1). In addition, specimens will be studied to determine expression of various lytic antigens. These histologic studies will ensure the highest standards of diagnostic accuracy with regards to the diagnosis of Hodgkin's disease and its subtyping. Serology specimens collected in the prospective and serum bank study will be evaluated. All of the sera will be titrated in traditional assays on EBV cell lines to detect IgG and IgA antibodies to VCA, EA-D, EA-R, and EBNA. In addition, titers to EBV antigens expressed in cell lines expressing individual EBV genes will be titrated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA069266-04
Application #
6344731
Study Section
Project Start
2000-08-18
Project End
2001-05-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
2000
Total Cost
$179,222
Indirect Cost
Name
Harvard University
Department
Type
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Levin, Lynn I; Breen, Elizabeth C; Birmann, Brenda M et al. (2017) Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis. Cancer Epidemiol Biomarkers Prev 26:1114-1123
Epstein, Mara M; Chang, Ellen T; Zhang, Yawei et al. (2015) Dietary pattern and risk of hodgkin lymphoma in a population-based case-control study. Am J Epidemiol 182:405-16
Li, Qian; Chang, Ellen T; Bassig, Bryan A et al. (2013) Body size and risk of Hodgkin's lymphoma by age and gender: a population-based case-control study in Connecticut and Massachusetts. Cancer Causes Control 24:287-95
Gao, Yongshun; Li, Qian; Bassig, Bryan A et al. (2013) Subtype of dietary fat in relation to risk of Hodgkin lymphoma: a population-based case-control study in Connecticut and Massachusetts. Cancer Causes Control 24:485-94
Levin, Lynn I; Chang, Ellen T; Ambinder, Richard F et al. (2012) Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma. Blood 120:3750-5
Kasperzyk, Julie L; Chang, Ellen T; Birmann, Brenda M et al. (2011) Nutrients and genetic variation involved in one-carbon metabolism and Hodgkin lymphoma risk: a population-based case-control study. Am J Epidemiol 174:816-27
Chang, Ellen T; Birmann, Brenda M; Kasperzyk, Julie L et al. (2009) Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 18:976-86
Fu, De-Xue; Tanhehco, Yvette; Chen, Jianmeng et al. (2008) Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med 14:1118-22
Chang, Ellen T; Zheng, Tongzhang; Weir, Edward G et al. (2004) Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 96:305-15
Chang, Ellen T; Zheng, Tongzhang; Lennette, Evelyne T et al. (2004) Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma. J Infect Dis 189:2271-81

Showing the most recent 10 out of 16 publications